ReviewBrain sciences2026
Parkinson's Disease: Conventional Pharmacotherapy, Drug Delivery Innovations, and Emerging Therapeutic Targets.
Review in Brain sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms (bradykinesia, rigidity, resting tremor) and a wide range of non-motor features. The core pathological process is degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine deficiency, while additional neurotransmitter systems contribute to non-motor symptoms. PD is a common age-related disorder; global estimates for 2019 indicate that more than 8.5 million people were living with PD, and prevalence increases steeply with age. Current pharmacological therapy is mainly symptomatic and is centered on levodopa and other dopaminergic strategies, but treatment response can be limited by motor fluctuations, dyskinesia, and adverse effects. Therefore, formulation and delivery innovations (e.g., dispersible preparations, intestinal gel, and continuous infusion approaches) aim to stabilize drug exposure and improve convenience, especially in patients with swallowing difficulties or advanced disease. This review summarizes conventional drug classes and their dosage forms, highlights formulation-driven strategies to improve efficacy and tolerability, and outlines emerging pathways and targets being explored for future therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.